|
1.
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
2.
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: the impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Leystra AA, Deming DA, Zahm CD, et al:
Mice expressing activated PI3K rapidly develop advanced colon
cancer. Cancer Res. 72:2931–2936. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Pal I and Mandal M: PI3K and Akt as
molecular targets for cancer therapy: current clinical outcomes.
Acta Pharmacol Sin. 33:1441–1458. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Oldham S and Hafen E: Insulin/IGF and
target of rapamycin signaling: a TOR de force in growth control.
Trends Cell Biol. 13:79–85. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Hietakangas V and Cohen SM: Regulation of
tissue growth through nutrient sensing. Annu Rev Genet. 43:389–410.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Michlig S, Harris M, Loffing J, Rossier BC
and Firsov D: Progesterone down-regulates the open probability of
the amiloride-sensitive epithelial sodium channel via a
Nedd4-2-dependent mechanism. J Biol Chem. 280:38264–38270. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Saif MW and Chu E: Biology of colorectal
cancer. Cancer J. 16:196–201. 2010. View Article : Google Scholar
|
|
10.
|
Walther A, Johnstone E, Swanton C, Midgley
R, Tomlinson I and Kerr D: Genetic prognostic and predictive
markers in colorectal cancer. Nat Rev Cancer. 9:489–499. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Tenbaum SP, Ordonez-Moran P, Puig I, et
al: beta-catenin confers resistance to PI3K and AKT inhibitors and
subverts FOXO3a to promote metastasis in colon cancer. Nat Med.
18:892–901. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Abdul-Ghani R, Serra V, Gyorffy B, et al:
The PI3K inhibitor LY294002 blocks drug export from resistant colon
carcinoma cells overexpressing MRP1. Oncogene. 25:1743–1752. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Martini M, Ciraolo E, Gulluni F and Hirsch
E: Targeting PI3K in cancer: any good news? Front Oncol. 3:1082013.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Vlahos CJ, Matter WF, Hui KY and Brown RF:
A specific inhibitor of phosphatidylinositol 3-kinase,
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol
Chem. 269:5241–5248. 1994.PubMed/NCBI
|
|
15.
|
Tumaneng K, Russell RC and Guan KL: Organ
size control by Hippo and TOR pathways. Curr Biol. 22:R368–R379.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Steinhardt AA, Gayyed MF, Klein AP, et al:
Expression of Yes-associated protein in common solid tumors. Hum
Pathol. 39:1582–1589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Konsavage WM Jr, Kyler SL, Rennoll SA, Jin
G and Yochum GS: Wnt/beta-catenin signaling regulates
Yes-associated protein (YAP) gene expression in colorectal
carcinoma cells. J Biol Chem. 287:11730–11739. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Avruch J, Zhou D and Bardeesy N: YAP
oncogene overexpression supercharges colon cancer proliferation.
Cell Cycle. 11:1090–1096. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Zhou D, Zhang Y, Wu H, et al: Mst1 and
Mst2 protein kinases restrain intestinal stem cell proliferation
and colonic tumorigenesis by inhibition of Yes-associated protein
(Yap) overabundance. Proc Natl Acad Sci USA. 108:E1312–1320. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Yuen HF, McCrudden CM, Huang YH, et al:
TAZ expression as a prognostic indicator in colorectal cancer. PloS
One. 8:e542112013. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Kim SJ, Chung MJ, Kim JS, et al:
Deciphering the role of paclitaxel in the SKGT4 human esophageal
adenocarcinoma cell line. Int J Oncol. 39:1587–1591.
2011.PubMed/NCBI
|
|
22.
|
Kim SJ, Lee JS and Kim SM:
3,3′-Diindolylmethane suppresses growth of human esophageal
squamous cancer cells by G1 cell cycle arrest. Oncol Rep.
27:1669–1673. 2012.
|
|
23.
|
Eisen MB, Spellman PT, Brown PO and
Botstein D: Cluster analysis and display of genome-wide expression
patterns. Proc Natl Acad Sci USA. 95:14863–14868. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Ahmad A, Ali S, Ahmed A, et al: 3,
3′-Diindolylmethane enhances the effectiveness of herceptin against
HER-2/neu-expressing breast cancer cells. PloS One.
8:e546572013.
|
|
25.
|
Bhatnagar N, Li X, Chen Y, Zhou X, Garrett
SH and Guo B: 3,3′-diindolylmethane enhances the efficacy of
butyrate in colon cancer prevention through down-regulation of
survivin. Cancer Prev Res. 2:581–589. 2009.
|
|
26.
|
Kim YH, Kwon HS, Kim DH, et al:
3,3′-diindolylmethane attenuates colonic inflammation and
tumorigenesis in mice. Inflamm Bowel Dis. 15:1164–1173. 2009.
|
|
27.
|
Pappa G, Strathmann J, Lowinger M, Bartsch
H and Gerhauser C: Quantitative combination effects between
sulforaphane and 3,3′-diindolylmethane on proliferation of human
colon cancer cells in vitro. Carcinogenesis. 28:1471–1477.
2007.
|
|
28.
|
Li Y, Li X and Guo B: Chemopreventive
agent 3,3′-diindolylmethane selectively induces proteasomal
degradation of class I histone deacetylases. Cancer Res.
70:646–654. 2010.
|
|
29.
|
Choi HJ, Lim do Y and Park JH: Induction
of G1 and G2/M cell cycle arrests by the dietary compound
3,3′-diindolylmethane in HT-29 human colon cancer cells. BMC
Gastroenterol. 9:392009.PubMed/NCBI
|
|
30.
|
Gao N, Cheng S, Budhraja A, et al:
3,3′-Diindolylmethane exhibits antileukemic activity in vitro and
in vivo through a Akt-dependent process. PloS One.
7:e317832012.
|
|
31.
|
Kim AH, Khursigara G, Sun X, Franke TF and
Chao MV: Akt phosphorylates and negatively regulates apoptosis
signal-regulating kinase 1. Mol Cellular Biol. 21:893–901. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Alessi DR, Andjelkovic M, Caudwell B, et
al: Mechanism of activation of protein kinase B by insulin and
IGF-1. EMBO J. 15:6541–6551. 1996.PubMed/NCBI
|
|
33.
|
Harvey KF, Zhang X and Thomas DM: The
Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Halder G and Johnson RL: Hippo signaling:
growth control and beyond. Development. 138:9–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Harvey K and Tapon N: The
Salvador-Warts-Hippo pathway - an emerging tumour-suppressor
network. Nat Rev Cancer. 7:182–191. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Lu L, Li Y, Kim SM, et al: Hippo signaling
is a potent in vivo growth and tumor suppressor pathway in the
mammalian liver. Proc Natl Acad Sci USA. 107:1437–1442. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Camargo FD, Gokhale S, Johnnidis JB, et
al: YAP1 increases organ size and expands undifferentiated
progenitor cells. Curr Biol. 17:2054–2060. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Cai J, Zhang N, Zheng Y, de Wilde RF,
Maitra A and Pan D: The Hippo signaling pathway restricts the
oncogenic potential of an intestinal regeneration program. Genes
Dev. 24:2383–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Ye X, Deng Y and Lai ZC: Akt is negatively
regulated by Hippo signaling for growth inhibition in Drosophila.
Dev Biol. 369:115–123. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Cinar B, Fang PK, Lutchman M, et al: The
pro-apoptotic kinase Mst1 and its caspase cleavage products are
direct inhibitors of Akt1. EMBO J. 26:4523–4534. 2007. View Article : Google Scholar : PubMed/NCBI
|
